<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972591</url>
  </required_header>
  <id_info>
    <org_study_id>TJ20210623</org_study_id>
    <nct_id>NCT04972591</nct_id>
  </id_info>
  <brief_title>Follow-up Study of Population Vaccinated With COVID-19 Vaccine</brief_title>
  <official_title>Follow-up Study of Population Vaccinated With COVID-19 Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qin Ning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yichang Central Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shiyan Renmin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The second Hospital of JingZhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Provincial Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WUHAN NO.7 HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Bethune Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centered clinical follow-up study to investigate the long-term dynamic of COVID-19&#xD;
      antibody level after vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From December 2019, coronavirus disease 2019 (COVID-19), caused by a Î²-coronavirus known as&#xD;
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the globe. As&#xD;
      of July 6, 2021, more than 180 million confirmed cases and around 4 million deaths have been&#xD;
      reported globally. Till now, many treatment methods has gradually formed a consensus. At the&#xD;
      same time, several domestic vaccines have been offered to the public for free inoculation in&#xD;
      our country. However, due to the urgent form of the epidemic, the short vaccine development&#xD;
      cycle and heavy tasks, there is no clear conclusion on the long-term changes in antibody&#xD;
      levels after vaccination.Therefore, we plan to carry out a multi-center prospective&#xD;
      observational trial to better understand the dynamic changes of the antibody levels in&#xD;
      patients after vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>symptoms and signs</measure>
    <time_frame>6months</time_frame>
    <description>symptoms and signs after vaccination will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibody levels</measure>
    <time_frame>6months</time_frame>
    <description>antibody levels will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory findings</measure>
    <time_frame>6months</time_frame>
    <description>Clinical laboratory examination were obtained during follow-up.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CHB Group</arm_group_label>
    <description>Patients with CHB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compared Group</arm_group_label>
    <description>Healthy people</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood mononuclear cell (PBMC)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All population who has been vaccinated or are prepared to get vaccinated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (18 years old or elder) who prepare or have been vaccinated against COVID-19,&#xD;
             and has not participated in similar clinical studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People who are allergic to any active ingredient of the vaccine, any inactive&#xD;
             ingredient which was used in the production process, or those who have been allergic&#xD;
             to the same kind of vaccine before.&#xD;
&#xD;
          -  People who have had severe allergic reaction to vaccine before (such as acute allergic&#xD;
             reaction, vascular neuroedema, dyspnea, etc.)&#xD;
&#xD;
          -  People with uncontrolled epilepsy and other serious neurological diseases (such as&#xD;
             transverse myelitis, Guillain-Barre syndrome, demyelinating diseases, etc.)&#xD;
&#xD;
          -  People who are feverish, or suffering from acute diseases, or suffering from acute&#xD;
             episodes of chronic diseases, or with serious chronic diseases without control.&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Juvenile&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qin Ning, Professor</last_name>
    <phone>+8613971521450</phone>
    <email>qning@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Ning, PHD,MD</last_name>
      <phone>+8602783662391</phone>
      <email>qning@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaoping Luo, PHD,MD</last_name>
      <email>xpluo888@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qin Ning, PHD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Chen, PHD,MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qin Ning</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Anti-body</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

